Toert schreef op 21 mei 2020 08:06:
Een stukje uit een Reuters bericht (van op Bolero) :
The fact that only the high dose worked and not the low-dose 100 mg could be the reason for investor pushback, Jefferies analyst Michael Yee said in a client note.
However, the positive data potentially drives filgotinib consensus sales to more than $3 billion globally, from over $2 billion, because the drug could also be approved for UC, Yee
said.
Eligible patients who completed treatment in the trial through week 58 were enrolled in an ongoing extension trial to evaluate the long-term safety of filgotinib in UC patients, the
companies said.